Cardiovascular Toxicity of BTKi in Chronic B-Cell Malignancies
Reviews in Cardiovascular Medicine · 26.06.2026 · 27 (6)
DOI: 10.31083/rcm47740 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Reviews in Cardiovascular Medicine, online erschienen am 26.06.2026. Verfasst von Haojian Gan und 8 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, Huzhou University, 313000 Huzhou, Zhejiang, China. Die Arbeit nennt 112 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Huzhou Science and Technology Bureau Public Welfare Application Research Project.
Abstract (Originalsprache)
Bruton's tyrosine kinase (BTK) inhibitors are important targeted drugs for treating chronic B-cell malignancies, and have played a key role in improving patient prognosis and treatment efficacy. However, despite the significant advantages of BTK inhibitors in anti-tumor therapy, the use of these drugs also promotes certain cardiovascular risks, including atrial fibrillation (AF), bleeding, hypertension, heart failure, and potential ventricular arrhythmias (VAs). The latest generation of BTK inhibitors has shown progress in reducing the incidence of these adverse events; however, cardiovascular adverse events (CVAEs) cannot be ignored and continue to pose challenges to patient safety. Therefore, determining how to optimize the clinical application of Bruton’s tyrosine kinase inhibitor (BTKi) further has become an urgent problem. This review systematically analyzes the pathogenesis and clinical manifestations of BTK inhibitor-related cardiovascular complications, with a particular focus on the epidemiological characteristics and potential risk factors of common adverse reactions, such as hypertension, AF, bleeding, and stroke. Moreover, this review explores the pathological and physiological mechanisms, further evaluates the effectiveness of current risk management and intervention strategies, and proposes future research to elucidate mechanisms, optimize doses, and explore combination therapy. Meanwhile, through in-depth analysis and comprehensive evaluation of existing data, this review aims to provide a more scientific basis for clinical decision-making, while promoting research into the safety of continuous BTK inhibitor use to achieve improved treatment outcomes while balancing efficacy and safety.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Medicine, Huzhou University, 313000 Huzhou, Zhejiang, China.
- Department of Cardiovascular Center, First affiliated Hospital of Huzhou University, 313000 Huzhou, Zhejiang, China.
- Department of Breast and Thyroid Surgery, First affiliated Hospital of Huzhou University, 313000 Huzhou, Zhejiang, China.
ORCID-Profile: Haojian Gan, Junling Lin, Jiayi Xu, Qingjian He, Shuo Chen, Yu Feng, Bicheng Hu, Wenjuan Wang
Förderung
- Huzhou Science and Technology Bureau Public Welfare Application Research Project
Zitieren
APA
Gan, H., Lin, J., Sun, Q., Xu, J., He, Q., Chen, S., Feng, Y., Hu, B., & Wang, W. (2026). Cardiovascular Toxicity of BTKi in Chronic B-Cell Malignancies. Reviews in Cardiovascular Medicine, 27(6). https://doi.org/10.31083/rcm47740
Vancouver
Gan H, Lin J, Sun Q, Xu J, He Q, Chen S, et al. Cardiovascular Toxicity of BTKi in Chronic B-Cell Malignancies. Reviews in Cardiovascular Medicine. 2026;27(6). doi:10.31083/rcm47740
BibTeX
@article{Gan2026,
author = {Gan, Haojian and Lin, Junling and Sun, Qiyin and Xu, Jiayi and He, Qingjian and Chen, Shuo and Feng, Yu and Hu, Bicheng and Wang, Wenjuan},
title = {Cardiovascular Toxicity of BTKi in Chronic B-Cell Malignancies},
journal = {Reviews in Cardiovascular Medicine},
year = {2026},
volume = {27},
number = {6},
doi = {10.31083/rcm47740}
}
EUVIMED